OPT
Director Trades
| Date | Director | Value |
|---|
Company News
Opthea achieves positive vision trial, eyes further clinical trials
Biopharmaceutical company Opthea (ASX: OPT) has taken an affirmative step towards commercialising its OPT-302 combination therapy after publishing positive phase 2b clinical trial results that included 366 patients. With the results published the biopharma company claims that PT-302 may emerge as a combination treatment that can offer better vision gains than currently available care with […]
Opthea starts trial for OPT-302 drug in diabetic eye diseases
Biopharmaceutical company Opthea (ASX: OPT) has started a Phase 1b/2a trial investigating the effectiveness of its OPT-302 drug in diabetic eye diseases. Diabetic macular edema leads to the thickening of the retina caused by leaky blood vessels. The disease is the leading cause of blindness in diabetes and affects more than two million people around […]